ElegsLab
PrivateLast Round
Angel
Jan 28, 2025
Company Overview
ElegsLab is a biotechnology company that provides an AI-driven drug discovery and preclinical CRO platform utilizing microfluidic biochips and C. elegans models.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Biotech Equipment, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS, Hardware Sales
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ElegsLab Comparables
Compare ElegsLab with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NemaLife | 87% | |
| vivoVerse | 86% | |
| Magnitude Biosciences | 84% | |
ElegsLab Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Angel | Jan 28, 2025 | ||||
| Seed | Dec 1, 2024 |
ElegsLab Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Busan United Technology Holdings | Angel, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 1, 2024
Seed round led by Busan United Technology Holdings.
ElegsLab Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ElegsLab's valuation, stock price, and market status.